Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment
This case suggests potential therapeutic benefit of RTX for refractory ocular symptoms in concurrent MG and TED. Quantitative T2 mapping revealed pathologically elevated values that normalized post-treatment, providing preliminary objective evidence of treatment response. As a single case, the relative contributions of MG versus TED pathology cannot be definitively separated. Integrating clinical assessment with quantitative T2 mapping may offer an objective approach for monitoring treatment response in such complex dual autoimmune disorders.
Authors
- Baitong Wang
- Dingxian He (ORCID: https://orcid.org/0009-0005-9955-7179)
- Jianying Xi
- Sushan Luo (ORCID: https://orcid.org/0000-0002-9033-7568)
- Chongbo Zhao (ORCID: https://orcid.org/0000-0002-0475-1798)
- Yaqi Wang (ORCID: https://orcid.org/0000-0002-7261-4947)
- Chong Yan (ORCID: https://orcid.org/0009-0009-1451-3388)
- Xiangwen Li (ORCID: https://orcid.org/0000-0002-8274-6679)
- Mengxiao Liu (ORCID: https://orcid.org/0000-0002-5076-4960)
- Tom Hibert
Institutions
- RAG Aktiengesellschaft (Germany) (DE)
- The Affiliated Hospital to Changchun University of Chinese Medicine (CN)
- Siemens Healthcare (United States) (US)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fimmu.2025.1717260
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00